Elequin Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Elequin Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13	Closed	-$2.6K	–	820
2026 Q1	$2.6K	Sell	13 -21	-62%	-$4.16K	﹤0.01%	460
2025 Q4	$6.43K	Buy	+34	New	+$6.53K	﹤0.01%	284
2022 Q2	–	Sell	-14	Closed	-$1K	–	418
2022 Q1	$1K	Buy	+14	New	+$1.02K	﹤0.01%	291

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elequin Capital's LGND Position: Q2 2026 in Review

Elequin Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 13 shares — an estimated $2.6K sold.

Elequin Capital first reported a position in LGND in Q1 2022 and held it in 3 quarters. The position peaked at $6.43K in Q4 2025. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Elequin Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Elequin Capital sold 13 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.6K.
Elequin Capital first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Elequin Capital's Ligand Pharmaceuticals position peaked at $6.43K in Q4 2025.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.